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preservation of mobility, control of pain, and delaying total knee
replacement (TKR). Objective: To estimate the cost-effectiveness of
viscosupplementation (hylan G-F 20) alone compared with conven-
tional supportive therapy (CST) in the treatment of knee OA in
Colombia. Methods: Microsimulation in patients with knee OA, mod-
eling of clinical outcomes (disease progression, symptom improve-
ment, TKR), and estimation of associated costs were performed
(drugs, diagnostic tests, procedures, and hospitalizations). The prob-
abilities for disease progression and clinical events were correlated
with patients’ characteristics. Clinical outcome information was
obtained from the literature. The costs were drawn from institutional
databases from health maintenance organizations and the Colombian
standard tariffs handbook (ISS 2001. Agreement No. 256 of 2001.
Tariffs for the health promoter Social Security EPS-ISS. Social Insur-
ance Board of Directors. December 19, 2001). Sensitivity analyses were
performed for costs and transition probabilities. Results: Monte-Carloee front matter Copyright & 2015, International S
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ndence to: Juan-Diego Misas, Transversal 23 #97-7simulation for 1000 patients with knee OA showed that viscosupple-
mentation with hylan G-F 20 delayed the occurrence of TKR by 3 years
compared with CST. Western Ontario and McMaster Universities
Arthritis Index scores indicate improvement in symptoms and func-
tion with hylan G-F 20. The incremental cost-effectiveness ratio for
viscosupplementation is dominant, with reduction of US $576 in
treatment cost in favor of hylan G-F 20, with more cost-effectiveness
per quality-adjusted life-year during the ﬁrst 10 years of treatment
compared with CST. Conclusions: The results of mathematical simu-
lation indicate that in comparison to conventional support therapies,
viscosupplementation with hylan G-F 20 improved disease symptoms,
joint function, and quality of life, reduced direct treatment costs,
delayed TKR by 3 years, and was cost-effective in Colombia.
Keywords: cost-effectiveness, hylan GF-20, osteoarthritis, total knee
replacement, viscosupplementation.
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Osteoarthritis (OA) is the most common chronic joint disease of
the cartilage. It is the sixth leading cause of “years of living with
disability” globally and will be the fourth leading cause of disability
by the year 2020 [1]. The incidence of OA increases with age [1,2].
The population affected by OA disability is expected to double by
the year 2020 [3].
Treatment strategies for OA include the use of a stepped care
strategy of intraarticular injections and total knee replacement
(TKR) [4]. Treatment goals for knee OA include preservation of
mobility, quality of life (QOL), control of pain, and slowing of
disease progression, to delay TKR, which is costly and may not be
medically desirable.
Viscosupplementation includes the injection of hyaluronan or
hylan G-F 20, which has been shown to be safe and effective.With appropriate care, viscosupplementation provides beneﬁts
for knee function, overall health, and health-related QOL at
reduced levels of cotherapy [5].
Studies conﬁrm that hylan G-F 20 viscosupplementation is
more effective than conventional treatment, at no additio-
nal cost [6], and reduces the economic burden of knee OA
treatment [7]. Adding one or more courses of hylan G-F 20
therapy to the standard treatment for 3 years indicated that
appropriate use could delay the need for TKRs and generate
savings [8–10].
In Colombia there are no data about the beneﬁts and costs of
hylan G-F 20 therapy in patients with OA and an economic
evaluation is needed. The aim of this study was to determine
the cost-effectiveness of hylan G-F 20 therapy compared with
conventional supportive therapy (CST) in the treatment of knee
OA in Colombia.ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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The model considered all grades of OA (Kellgren & Lawrence grades
1–4), which were stratiﬁed by ages. For the simulations, it consid-
ered a cohort of 1000 patients aged between younger than 50 years
and older than 80 years. At all age groups (o50, 50–59, 60–69, 70–79,
and 480 years), 59% of the patients were men and 41% were
women. The age group of 70 to 79 years had the highest number of
patients (357 patients). Disease severity was calculated by taking all
grades of OA into consideration, and the distribution of knee OA
was based on disease severity as reported in Table 1. Most of the
patients (70%) were placed in grades 2 and 3 severity scale.
Simulation Methodology
A microsimulation of clinical outcomes (disease progression,
viscosupplementation, symptom improvement, and frequency
of TKR) was done focused on a hypothetical cohort of 1000
patients with knee OA and simulated, with annual regularity,
their disability over time. Clinical data including the probability
of disease progression were obtained from the published liter-
ature [10–12]. The use of hylan G-F 20 was compared with the use
of CST. Treatment outcomes were simulated at different time
horizons in the interval of 5 to 20 years.
In this model, functional disability is expressed in terms of
scores obtained on the Western Ontario McMaster University
Osteoarthritis Index (WOMAC) and then translated into quality-
adjusted life-years (QALYs) [13]. The WOMAC score dimensions
are pain, stiffness, and functional capacity on a scale ranging
from 0 through 96.
Discrete-event simulation [14] was used considering patient’s
ages, sex, disease progression, and initial disease severity.
Discrete-event simulation allowed modeling of different charac-
teristics of the patients (age, sex, disease progress) over time.
Patients were divided proportionally into four subgroups accord-
ing to the prevalence of the OA grade according to Lussier et al.
[12]. Upon entry to the model, an initial WOMAC score is
randomly assigned to each patient on the basis of baseline
pretreatment WOMAC scores for the population. Initial scores
vary from patient to patient. Annual variation depends on clinical
outcome, categorized as follows: 1) symptom improvement, 2) no
change in symptoms, 3) worsening of symptoms, and 4) TKR.
The annual change in WOMAC scores for patients receiving
hylan G-F 20 is estimated on the basis of results of randomized
controlled trials [15–18]. The available evidence suggests that the
beneﬁt obtained by viscosupplementation with hylan G-F 20 is
sustained over time [10–12,15–23]; in light of this, the WOMAC
scores after the ﬁrst year are assigned randomly taking into
account the clinical outcome for the previous years. The infor-
mation about score variation is available as reported by Raman
et al. [24]. In this study, the average of the percentage change of
decrease in the WOMAC scores was 9.4, 25.9, and 24.5 points on a
scale ranging from 0 to 96 at 6 weeks, 6 months, and 12 months,
respectively. It is assumed that the change in percentage for
the scores has a normal distribution, based on kurtosis andTable 1 – Distribution of knee osteoarthritis based
on disease severity.
Severity scale according to Kellgren &
Lawrence
% of patients
[19]
Grade 1 22.4
Grade 2 37.4
Grade 3 33.5
Grade 4 6.7skewedness tests for the whole of the patient data. Because of
the lack of available scientiﬁc evidence showing the distribution of
WOMAC scores according to OA degrees, in order for the model to
have an adjudication rule for assigning the degree of OA according
to the compounded WOMAC score, an arbitrary classiﬁcation was
made for each of the dimensions in the scale, dividing the scale
into four equal portions. This was done with the objective of
assigning treatment costs according to OA degrees.
It was assumed that hylan G-F 20 was given once or twice a
year (one 6-ml injection per application) [25]. CST included
analgesics (nonsteroidal anti-inﬂammatory drugs and opioids),
intraarticular corticosteroids, and arthroscopy for debridement
and/or correction of associated injuries; physiotherapy; and
recommendations of lifestyle changes (weight loss). In most
cases, the common outcome for the terminal degenerative dis-
ease is surgical treatment with TKR.
Each replication was of 1000 patients. Each run is of N
replications, allowing for a 95% conﬁdence interval calculation
[22]. The expected results include the average WOMAC score at
the beginning and in the subsequent years and QALYs until the
end of the stipulated time horizon.
The model was implemented using Microsoft Excel and Visual
Basic macros, taking into account, in order to perform the
dynamic simulation for the patients in the cohort, randomization
of variables and the calculation of results derived from them.
The costs of the two treatments were taken from Sistema de
Información de Precios de Medicamentos (SISMED) (Drug Information
System of the Ministry of Social Protection) and “Farmaprecios”
database. Other direct costs generated by medical services necessary
tomanage the disease (e.g., physical therapy) were also included. The
accounting of medication costs has included drug acquisition and
administration, pretreatment evaluation, routine laboratory parame-
ters, and diagnostic imaging. These costs and TKR costs were taken
mainly from Seguro Obligatorio de Accidentes de Tránsito (SOAT)
tariff Manual 2012 and ISS 2001 tariffs [26].
Various conventional alternatives for support therapies for
the knee OA treatment were considered in this study, and several
simulations were performed to identify all the relevant costs and
consequences for each one. Direct, average, and total costs, cost-
effectiveness ratios, and incremental cost-effectiveness ratios
(ICER) were all used to compare hylan G-F 20 viscosupplementa-
tion against CST.
Results of treatment were considered in certain horizons, but
the reference case was predeﬁned as 20 years of follow-up. During
the simulation, the expected values for all economic and clinical
outcomes were obtained for each patient. The summary of results
across all patients in the cohort provides expected values for the
group as a whole.
The cost-effectiveness ratio was expressed in terms of incre-
mental cost per QALY gained compared with CST [27]. The
analysis was made from the third-party payer perspective, the
costs and effectiveness were discounted at an annual discount
rate of 3%, and alternative rates were used as appropriate for
sensitivity analysis. To address the uncertainty about model
inputs, a ﬁrst-order Monte-Carlo simulation was used. In a
second-order Monte-Carlo simulation, the model was run for
100 replications, allowing calculation of the mean values and the
95% conﬁdence intervals for clinical outcomes, cost acceptability
curves, and cost-effectiveness ratio. The parameter variations
were applied simultaneously in probabilistic sensitivity analysis
on the basis of their respective estimated distribution, which
includes 1) percentage variation in the WOMAC score to 6 months
(which can be interpreted as efﬁcacy); 2) health state utilities for
the WOMAC interval; and 3) cost of health care services by the
WOMAC interval as explained above. Sensitivity analyses were
performed for costs and transition probabilities between degrees
of knee OA.
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Annual progression of the disease comparing the use of hylan G-
F 20 alone and CST was calculated, taking into consideration the
state of the symptoms (improved, unchanged, and deteriorated),
as presented in Table 2. Annual disease progression comparison
results indicate that 87% of the patients treated with hylan G-F 20
show improved symptoms compared with 25% of the patients
treated with CST. The simulation showed that only 6.4% of group
4 patients treated with hylan G-F 20 underwent TKR while 12.8%
of the patients under CST had a need for it. In patients with grade
4 OA treated with viscosupplementation using hylan G-F 20, the
occurrence of TKR is delayed by 3 years, compared with patients
treated with CST.
Through the simulation run, the average total cost by patient
was US $27,541 for hylan G-F 20 and US $ 27,203 for CST in a 20-
year time horizon. The comparison between the average costs of
the two alternatives was performed as shown in Figure 1. These
results have indicated that the average cost was slightly higher
for CST than for hylan G-F 20 in the ﬁrst years of simulation and
tends to be progressively less different by the 20th year.
Economic evaluations were performed using pain, stiffness,
and functional ability; QALY was the main parameter used to
evaluate the economic beneﬁt of treatment. QALY for hylan G-F
20 was 15.43 as compared with 14.34 for CST, resulting in a
signiﬁcant improvement of 1.09 in favor of hylan G-F 20. Visco-
supplementation with hylan G-F 20 improved the patient’s QOL
as compared with CST.
The cost-effectiveness plane was plotted using difference in
QALY versus difference in costs as shown in Figure 2. Monte-
Carlo simulations were used to generate an ICER calculated from
the simulated data and repeated several times to get ICER
distribution. In the scatter plot of incremental costs and QALY,
most of the points were located in the right quadrants of the cost-
effectiveness plane, suggesting a greater effectiveness for hylan
G-F 20. Considering that hylan G-F 20 treatment is more effective
and is less costly, it dominates CST, with most of the results of
microsimulations falling in the quadrant that represents higher
clinical beneﬁts and lower costs.
In a 10-year follow-up simulation period, the ICER for visco-
supplementation was dominant, with the following average
values, respectively, for hylan G-F 20 and CST: QALY of 8.12 and
7.81 (0.31 in favor of hylan G-F 20) and treatment costs of US
$14.128 and US $13.552, with a reduction of US $576 in favor of
hylan G-F 20.Table 2 – Comparative annual disease progression
using hylan G-F 20 and conventional support
therapy.
Outcome Hylan
G-F 20
(% of
patients)
Conventional
support
therapy
(% of patients)
Improved symptoms 87 [17] 33.3*
Unchanged symptoms 9 [17] 33.3*
Deteriorated symptoms 4 [17] 33.3*
Total knee replacement
(group 4)
6.4 [17] 50*
* Equal probabilities of disease progression with conventional
support therapy are assumed, considering that there is no data
available in the literature to allow direct comparison with hylan
G-F 20.A cost-effectiveness scatter plot graph was obtained from the
model execution, using deltas of QALYs versus deltas of costs
between evaluated alternatives at 5, 10, 15, and 20 years of
simulation, as shown in Figure 3. It can be perceived that to the
extent that the time horizon progressed from 5 to 20 years, most
of the points appeared in the quadrant at the bottom right of the
graph (zone of higher effectiveness and lower cost), indicating
that treatment with hylan G-F 20 tended to dominate the
comparator, especially during the ﬁrst 10 years of simulation.Discussion
A pharmacoeconomic comparison between viscosupplementa-
tion using hylan G-F 20 against CST in treatment of knee OA was
performed to assess differences in relevant outcomes, such as
WOMAC scores and costs. Published data on disease progression
and treatments indicated that more patients treated with hylan
G-F 20 showed clinical improvement than did those treated with
CST. The number of patients who underwent TKR was higher in
the CST group than in the hylan G-F 20 group, which can be
considered an important indicator of tendency for cost savings
given the expensive surgical procedure [8,19]. Viscosupplemen-
tation delayed the occurrence of TKR. The initial evidence
showed that hylan G-F 20 delayed TKR by an average of 2.67
years [7]. The model built here, however, has included data [10]
that reported a TKR delay of 3.8 years with the use of hylan G-F 20
in Kellgren & Lawrence grade 4 osteoarthritis in 75% of the knees
and combined it with the results reported as well [11]. The ability
of hylan G-F 20 to delay TKR is advantageous for patients for
whom TKR is not medically appropriate [10].
Comparison of WOMAC scores of function, pain, and stiffness
for a time period of up to 20 years showed that viscosupplemen-
tation using hylan G-F 20 resulted in better scores for function,
pain, and stiffness, indicating improvements in joint function
and symptoms. Viscosupplementation improved the QOL in the
present model as observed previously [22].
Cost comparisons and economic evaluations of treatments
using discrete-event simulation models are helpful to inform
decisions regarding resources utilization, offering ﬂexibility to
represent different stages of a disease, patient ages, sex, and
disease progression [27,28]. This model followed Drummond’s
methods of economic evaluation for comparison of treatment
options. In the simulation, calculations of 95% conﬁdence inter-
vals on clinical outcomes, cost-effectiveness acceptability curves,
cost-effectiveness, and sensitivity analysis were performed. The
reduction of direct costs in favor of viscosupplementation com-
pared with CST was signiﬁcant in the treatment of knee OA.
Comparisons of average direct costs showed that CST was
slightly more expensive than hylan G-F 20 therapy.
QALY is usually the chosen parameter for the measurement of
effectiveness of a treatment in cost-effectiveness evaluations,
considering that this parameter merges time (in years) and QOL
(in this model, provided by WOMAC scores). Knee OA, however, is
not a life-threatening condition; the number of life-years lived is
similar between different knee OA treatments. QOL by itself can
be signiﬁcantly improved by more effective treatments through
reduction of pain and suffering and improvement of function.
Literature shows that there is no signiﬁcant difference in the
values of QALYs between the compared therapies but there is a
signiﬁcant difference in QOL when effective therapies such as
viscosupplementation are used. Achieving gain in QALYs by way
of change in QOL is more difﬁcult than when QALY changes in
terms of the amount of life [29].
In the scatter plot of incremental costs and QALYs, most of
the points suggested a greater effectiveness and domination of
viscosupplementation over CST. If the simulation points fall
Fig. 1 – Comparison of average cost between between hylan G-F 20 and conventional support therapy was done by plotting the
average cost of treatment (US $) versus time in years. Solid line represents the average cost of hylan G-F 20. Dotted line
represents the average cost of conventional support therapy.
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costly and more effective) and 95% of the joint density is in two
quadrants, it involves cost savings [27]. After 10 years of simu-
lation follow-up, the intervention was dominant for viscosupple-
mentation. The results indicate that viscosupplementation with
hylan G-F 20 was better in terms of both cost and health
outcomes.
The ﬁndings in the present model show that the use of
viscosupplementation with hylan G-F 20 is cost-effective (domi-
nant) during the ﬁrst 10 years of treatment and becomes less
beneﬁcial after this period and progressively until the 20th year of
simulation because of the joint deterioration related to aging,
disease progression, and a higher probability of a TKR after
10 years.
The simulation allows asserting that viscosupplementation is
an attractive alternative for both QOL and economics in the
management of patients with knee OA who have dysfunction,
stiffness, and/or pain. The differences in the ratio of cost-
effectiveness are mainly explained by the increased likelihood
of having a knee replacement due to aging and disease pro-
gression. The SD also increases because there is variability in
clinical outcomes. To the extent that the disease progresses,Fig. 2 – The cost-effectiveness plane was plotted using the differ
effectiveness of hylan G-F 20 treatment over conventional suppthere are changes in associated costs showing an increasing
trend.
Cost-effectiveness models of hylan G-F 20 for knee OA were
developed earlier [7,20,21] using dynamic simulation techniques
to estimate the impact of functional disability and economic
outcomes in patients that resulted in 3-year savings [9]. Visco-
supplementation had a budgetary impact that led to net savings
during 10 years and reduced the economic burden of knee OA on
the health system by delaying TKR [7], supporting the results
presented in this article.
One of the strengths of the model is that it takes all grades of
OA (Kellgren & Lawrence grades 1–4) and is stratiﬁed by ages. One
of the main limitations of the present study is that most of the
variables were taken from the literature using populations that
may differ from the Colombian population, where epidemiolog-
ical data, disease management, and progression can be different.
This could change the results of the model.
The model developed for this article allowed us to assess the
cost-effectiveness of hylan G-F 20 and CST therapies in Colombia.
Hylan G-F 20 viscosupplementation is an attractive alternative for
patients with knee OA from both the clinical perspective and the
economic perspective.ence in QALYs versus difference in costs to look at the cost-
ort therapies. QALY, quality-adjusted life-year.
Fig. 3 – The cost-effectiveness plane was plotting using differences in QALYs versus difference in costs for 5, 10, 15, and 20
years. QALY, quality-adjusted life-year.
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The results of a simulation using a mathematic model developed
to perform a comparison of viscosupplementation with hylan G-F
20 versus CST in Colombia has shown an improvement in disease
symptoms, joint function, and QOL, with a decrease in direct
costs for the treatment of patients with knee OA. It was also
shown that viscosupplementation delayed the need for TKR by 3
years compared with CST. Viscosupplementation with hylan G-F
20 is dominant, in the pharmacoeconomic context, especially
during the early years.
Source of ﬁnancial support: This study was ﬁnanced by the
Sanoﬁ group. The authors received editorial/writing support in
the preparation of this manuscript funded by Sanoﬁ. RANDOM
Foundation (Bogotá, Colombia) participated as consultants. Edi-
torial assistance was provided by Madhavi Konduri of Pharma-
Science Corporate Solutions, Inc. The authors, however, are fully
responsible for all content and editorial decisions.
R E F E R E N C E S[1] Symmons D, Mathers C, Pﬂeger B. WHO report—Global burden of
osteoarthritis in the year 2000. Available from: http://www.who.int/
healthinfo/statistics/bod_osteoarthritis.pdf. [Accessed October 27,
2013].
[2] Lopez A, Lorenzo A, Lorenzo G. Osteoartritis de la rodilla, tratamiento
artroscópico: ¿mito o realidad? Rev Cubana Ortop Traumatol. Available
from: ISSN 1561-3100, 2007;21:2.
[3] Elders MJ. The increasing impact of arthritis on public health. J
Rheumatol 2000;60(Suppl.):6–8.
[4] Smink AJ, van den Ende CH, Vliet Vlieland TP, et al. “Beating
osteoARThritis”: development of a stepped care strategy to optimize
utilization and timing of non-surgical treatment modalities for
patients with hip or knee osteoarthritis. Clin Rheumatol 2011;30:
1623–9.
[5] Reynolds DL, Chambers LW, Badley EM, et al. Physical disability among
Canadians reporting musculoskeletal diseases. J Rheumatol
1992;19:1020–30.
[6] Kahan A, Lleu PL, Salin L. Prospective randomized study comparing the
medicoeconomic beneﬁts of Hylan GF-20 vs. conventional treatment in
knee osteoarthritis. Joint Bone Spine 2003;70:276–81.
[7] Mar J, Romero Jurado M, Arrospide A, et al. Cost-analysis of
viscosupplementation treatment with hyaluronic acid in candidate
knee replacement patients with osteoarhritis [in Spanish]. Rev Esp Cir
Ortop Traumatol 2013;57:6–14.
[8] Waddell DD. Viscosupplementation with hyaluronans for osteoarthritis
of the knee: clinical efﬁcacy and economic implications. Drugs Aging
2007;24:629–42.
[9] Waddell D, Rein A, Panarites C, et al. Cost implications of introducing
an alternative treatment for patients with osteoarthritis of the knee in
a managed care setting. Am J Manag Care 2001;7:981–91.[10] Waddell DD, Bricker DC. Total knee replacement delayed with Hylan
GF-20 use in patients with grade IV osteoarthritis. J Manag Care Pharm
2007;13:113–21.
[11] Van Saase JL, van Romunde LK, Cats A, et al. Epidemiology of
osteoarthritis: Zoetermeer survey. Comparison of radiological
osteoarthritis in a Dutch population with that in 10 other populations.
Ann Rheum Dis 1989;48:271–80.
[12] Lussier A, Cividino AA, McFarlane CA, et al. Viscosupplementation with
hylan for the treatment of osteoarthritis: ﬁndings from clinical practice
in Canada. J Rheumatol 1996;23:1579–85.
[13] Barton GR, Sach TH, Jenkinson C, et al. Do estimates of cost-utility
based on the EQ-5D differ from those based on the mapping of utility
scores? Health Qual Life Outcomes 2008;6:51.
[14] Karnon J, Stahl J, Brennan A, et al. Modeling using discrete event
simulation: a report of the ISPOR-SMDM Modeling Good Research
Practices Task Force-4. Value Health 2012;15:821–7.
[15] Migliore A, Giovannangeli F, Granata M, Laganà B. Hylan g-f 20: review
of its safety and efﬁcacy in the management of joint pain in
osteoarthritis. Clin Med Insights Arthritis Musculoskelet Disord
2010;3:55–68.
[16] Bellamy N, Campbell J, Robinson V, et al. Viscosupplementation for the
treatment of osteoarthritis of the knee (review). Cochrane Database
Syst Rev 2006;19: CD005321.
[17] Caborn D, Rush J, Lanzer W, et al. Efﬁcacy and tolerability of hylan GF-
20 and triamcinolone hexacetonide in patients with osteoarthritis of
the knee. J Rheum 2004;31:333–43.
[18] Waddell DD, Bricker DC. Clinical experience with the effectiveness and
tolerability of hylan GF-20 in 1047 patients with osteoarthritis of the
knee. J Knee Surg 2006;19:19–27.
[19] Bert JM, Waddell DD. Viscosupplementation with hylan gf-20 in
patients with osteoarthrosis of the knee. Ther Adv Musculoskelet Dis
2010;2:127–32.
[20] Halpern EF, Weinstein MC, Hunink MG, et al. Representing both ﬁrst-
and second-order uncertainties by Monte Carlo simulation for groups
of patients. Med Decis Making 2000;20:314–22.
[21] Craig BA, Black MA, Sendi PP. Uncertainty in decision models analyzing
cost-effectiveness. Med Decis Making 2000;20:135–7.
[22] Raynauld JP, Torrance GW, Band PA, et al. A prospective, randomized,
pragmatic, health outcomes trial evaluating the incorporation of hylan
GF-20 into the treatment paradigm for patients with knee osteoarthritis
(part 1 of 2): clinical results. Osteoarthritis Cartilage 2002;10:506–17.
[23] Stitik TP, Kazi A, Kim J. Synviscs in knee osteoarthritis. Future
Rheumatol 2008;3:215–22.
[24] Raman R, Dutta A, Day N, et al. Efﬁcacy of Hylan GF-20 and sodium
hyaluronate in the treatment of osteoarthritis of the knee—a
prospective randomized clinical trial. Knee 2008;15:318–24.
[25] Synvisc One [product information leaﬂet]. Ridgeﬁeld: Genzyme
Biosurgery, 2011.
[26] ISS 2001—Agreement No. 256 of 2001. Tariffs for the health promoter Social
Security EPS-ISS. Social Insurance Board of Directors. December 19, 2001.
[27] Drummond MF, O’Brien BJ, Stoddart GL, et al. Methods for the
Economic Evaluation of Health Care Programmes. New York: Oxford
University Press, 2003.
[28] Stahl JE. Modeling methods for pharmacoeconomics and health
technology assessment: an overview and guide. Pharmacoeconomics
2008;26:131–48.
[29] Sassi F. Calculating QALYs, comparing QALY and DALY calculations.
Health Policy Plan 2006;21:402–8.
